Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?

Area of Science:

• Oncology
• Vascular Biology

Background:

• Angiogenesis inhibition is a promising therapeutic strategy for various diseases, notably cancer.
• The field has seen significant advancements, including FDA approval of the first specific angiogenesis inhibitor for colorectal cancer.

Purpose of the Study:

• To review the current landscape of angiogenesis inhibition in disease treatment.
• To discuss the potential benefits and challenges of anti-angiogenesis therapies.

Main Methods:

• Review of existing literature on angiogenesis inhibitors.
• Analysis of approved and late-stage clinical development compounds.
• Discussion of mechanisms of action for indirect inhibitors.

Main Results:

• Several angiogenesis inhibitors are approved or in late-stage development, primarily targeting cancer.
• Current indirect inhibitors work by targeting angiogenic growth factors or their signaling pathways.
• A significant challenge with these therapies is the potential for induced resistance.

Conclusions:

• Anti-angiogenesis therapy offers a valuable approach for treating diseases beyond cancer.
• Further research into fundamental mechanisms is essential for developing next-generation anticancer strategies.
• Overcoming treatment resistance remains a key challenge for the future of angiogenesis inhibition.